Updates are available Correction dated 2021-07-27

Article History

First Online: 23 July 2020

Change Date: 27 July 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40263-021-00845-6

Compliance with Ethical Standards

:

: Open Access funding enabled and organized by Projekt DEAL. The authors were supported via the Center for Personalized and Translational Epilepsy Research with a LOEWE grant from the State of Hessen.

: Felix Rosenow reports grants and personal fees from UCB Pharma, Arvelle Therapeutics, and Desitin Arzneimittel; personal fees from Eisai, GW Pharmaceuticals, Novartis, Medtronic, Cerbomed, Sandoz, BayerVital, and Shire; and grants from the European Union, Deutsche Forschungsgemeinschaft, the LOEWE-Programm of the state of Hesse, and the Detlev-Wrobel-Fonds for Epilepsy Research. Adam Strzelczyk reports personal fees and grants from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals, LivaNova, Marinus Pharmaceuticals, Medtronic, Sage Therapeutics, UCB Pharma, and Zogenix. Laurent M. Willems, Sebastian Bauer, Martin Voss, and Kolja Jahnke report no conflicts of interest. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.

: All authors approved the final manuscript for submission.

: LMW developed the idea for this review. AS and LMW drafted the concept and performed the literature search and data analysis. LMW and AS wrote the manuscript, and SB, KJ, MV and FR critically revised the work. All authors contributed to the final manuscript.